TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1488359
Drug: Aminophylline i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline i.v. infusion at a rate of 500 mg/hour
Study: 22776634
Drug: Lurasidone 40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40-160 mg/d
Study: 31235074
Drug: Tisseel (fibrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisseel (fibrin sealant) in combination with surgical anastomosis
Study: 31002834
Drug: Oral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sedation with triazolam and intravenous placebo
Study: 31002834
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with midazolam and oral placebo
Study: 25801552
Drug: sublingual artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual artemether (ArTiMist) 3.0 mg/kg
Study: 25801552
Drug: sublingual artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual artemether
Study: 21864137
Drug: Phytoestrogen supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogen supplements with exercise
Study: 19675959
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) program
Study: 9062473
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (rhGH) 9.5 micrograms/kg daily for 9 months
Study: 7691256
Drug: rhGM-CSF (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (400 micrograms) for 7 days subcutaneously after chemotherapy
Study: 26315844
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (2 or 6 months)
Study: 26315844
Drug: Ambulatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory treatment
Study: 23011560
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral gabapentin
Study: 20556208
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of long-acting beta2-agonist (LABA) for 12 weeks with conventional reversibility test (2 puffs terbutaline)
Study: 20556208
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of long-acting beta2-agonist (LABA) for 12 weeks with reversibility test using refracted doses (1 puff every 5 min, total 4 puffs)
Study: 18652709
Drug: Penile block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile block using 0.25 mL kg(‐1) 0.5% bupivacaine (Group P)
Study: 18652709
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block using 0.5 mL kg(‐1) 0.25% bupivacaine with 0.5 mg kg(‐1) ketamine (Group C)
Study: 10553833
Drug: 50% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% ropivacaine (1%) and 50% lidocaine (2%) with 25 U hyaluronidase per mL
Study: 10553833
Drug: 50% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% bupivacaine (0.5%) and 50% lidocaine (2%) with 25 U hyaluronidase per mL
Study: 8656441
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin [100 mg/m2] on day 1, followed by fluorouracil [1000 mg/m2 per day] on days 1-5)
Study: 20558006
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg)
Study: 1804657
Drug: Niacin (50
Normalized name: niacin (inositol niacinate) 400 mg niacin (500 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (50 mg)
Study: 3409138
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug
Study: 28566591
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day) plus Aspirin (100 mg/day)
Study: 31153838
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Therapy (BMT)
Study: 15129422
Drug: Nefazodone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (maximum dose 600 mg/day; average dose 463 mg/day)
Study: 15129422
Drug: Sertraline (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (maximum dose 200 mg/day; average dose 153 mg/day)
Study: 15129422
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Nefazodone and Sertraline)
Study: 9515532
Drug: Urinary trypsin
Normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary trypsin inhibitor (UTI) administered for 5 consecutive days at a dose of 300,000 units per day
Study: 9515532
Drug: Urinary trypsin
Normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary trypsin inhibitor (UTI)
Study: 8070304
Drug: Dexfenfluramine 15
Normalized name: dexfenfluramine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 15 mg twice daily for 4 weeks
Study: 3123117
Drug: Oral etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etidronate (700‐1400 mg daily for 1 month)
Study: 3123117
Drug: Intravenous etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous etidronate (300 mg daily for 5 days)
Study: 23474847
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% strontium chloride (TriCalm®)
Study: 16506054
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin inhalation powder (HIIP) plus insulin glargine
Study: 16506054
Drug: Subcutaneously injected
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected insulin (SC insulin) plus insulin glargine
Study: 11078261
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg/twice daily) for 72 hours
Study: 1471412
Drug: Alum-adsorbed vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adsorbed vaccine (Control)
Study: 6319337
Drug: Purified form
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified form of wheat fibre (10.5 g/d)
Study: 2877413
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion with isotonic saline
Study: 26056101
Drug: RPT 450
Normalized name: rPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RPT 450 mg
Study: 26056101
Drug: RPT 600
Normalized name: rPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RPT 600 mg
Study: 26056101
Drug: RMP 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP 600 mg
Study: 23435121
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment with additional computerized probe procedure for attentional bias modification
Study: 20795418
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg every 8 hours)
Study: 18408370
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation, 1 mg/day
Study: 6994960
Drug: Phenytoin therapy
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin therapy
Study: 10643696
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (various second-line drugs including methotrexate, cyclosporine plus MTX, and others)
Study: 1521940
Drug: CK: carbonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK: carbonated 10% glucose-fructose solution
Study: 1521940
Drug: NCK: non-carbonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCK: non-carbonated 10% glucose-fructose solution
Study: 1521940
Drug: CNK: carbonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNK: carbonated non-caloric solution
Study: 1521940
Drug: NCNK: non-carbonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCNK: non-carbonated non-caloric solution
Study: 6476044
Drug: Intact capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact capsule
Study: 29045255
Drug: Relaxing music
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxing music therapy intervention (20 minutes, 3 times a day for 3 consecutive days)
Study: 22052702
Drug: DRAAAS (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRAAAS (dose regimen of artesunate and amodiaquine based on arm span- or age range)
Study: 22052702
Drug: SDRAA (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDRAA (standard dose regimen of artesunate and amodiaquine calculated according to body weight)
Study: 12181715
Drug: Oral sip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sip feed containing 500 kcal of energy and 16.66 g of protein in addition to daily oral intake
Study: 8076537
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal solution 2 sprays per nostril bid
Study: 8076537
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal solution 2 sprays per nostril qd
Study: 8076537
Drug: Chlorpheniramine 12
Normalized name: Chlorpheniramine 12 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 12 mg bid
Study: 2635353
Drug: Mexiletine 250
Normalized name: mexiletine 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 250 mg i.v. + 200 mg orally followed by 200 mg every 8 h for 48 h
Study: 337854
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg or 10 mg alone or with promethazine 6.25 mg, 12.5 mg, or 25 mg
Study: 337854
Drug: Promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 25 mg alone
Study: 337854
Drug: Promethazine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine doses larger than 12.5 mg
Study: 337854
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (morphine and promethazine)
Study: 30955985
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus baclofen 10 mg
Study: 30955985
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus metaxalone 400 mg
Study: 30955985
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus tizanidine 2 mg
Study: 27127346
Drug: Erythromycin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (12 months treatment, group A)
Study: 27127346
Drug: Erythromycin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (6 months treatment followed by 6 months follow-up, group B)
Study: 23829810
Drug: Customized aromatherapy
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized aromatherapy treatment
Study: 31738736
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (1,000 mg daily for 8 weeks)
Study: 31738736
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching capsules for 8 weeks)
Study: 28636184
Drug: Bococizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bococizumab (150 mg subcutaneously) administered to the abdomen
Study: 28636184
Drug: Bococizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bococizumab (150 mg subcutaneously) administered to the thigh
Study: 28636184
Drug: Bococizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bococizumab (150 mg subcutaneously) administered to the upper arm
Study: 25399048
Drug: NEMEX therapy
Normalized name: Nemex
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEMEX therapy twice a week
Study: 25399048
Drug: Optimized analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized analgesics and antiinflammatory drug use (acetaminophen and oral NSAIDs)
Study: 23246422
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (Lidocaine)
Study: 23246422
Drug: Neomycin‐Bacitracin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin‐Bacitracin combination spray
Study: 12714786
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg/m(2) orally)
Study: 8820004
Drug: Brodimoprim 200
Normalized name: brodimoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 200 mg tablets, single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients)
Study: 8820004
Drug: Brodimoprim 200
Normalized name: brodimoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 200 mg tablets, single daily dose of two tablets for 2 days (63 patients)
Study: 8820004
Drug: Pefloxacin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin, single dose of two 400 mg tablets for 1 day (51 patients)
Study: 3555589
Drug: Perceived best
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived best therapy
Study: 24290414
Drug: Losartan/hydrochlorothiazide 50
Normalized name: losartan/hydrochlorothiazide 50 mg-12.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/hydrochlorothiazide 50 + 12.5 mg tablet (EPR0001)
Study: 24290414
Drug: Preminent® reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preminent® reference formulation of losartan/hydrochlorothiazide 50 + 12.5 mg tablet
Study: 20795844
Drug: Charcoal cookie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal cookie (3 cookies, equivalent to 7.2 g of charcoal)
Study: 20795844
Drug: Aqueous activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous activated charcoal suspension (7.2 g)
Study: 20795844
Drug: Palatability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatability of aqueous activated charcoal suspension
Study: 11886970
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg intramuscular injections weekly
Study: 11886970
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GSTM) 50 mg intramuscular injections weekly
Study: 3287737
Drug: Norfenefrine 15-30
Normalized name: norfenefrine
DrugBank: Norfenefrine (DB13378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfenefrine 15-30 mg t.i.d. for 6 weeks
Study: 18713456
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (IDV) 800 mg q8h for 3 days
Study: 18713456
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (IDV) 800 mg q8h for 3 days and then IDV and American ginseng (AG) 1g q8h for 14 days
Study: 12675761
Drug: Nasal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation with hypertonic saline, 3 times daily for 6 weeks
Study: 3000923
Drug: Polyvalent intravenous
Normalized name: antivenin (Crotalidae) polyvalent intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent intravenous immune globulin (20 cc/kg weekly doses before and after transplantation)
Study: 3000923
Drug: Cytomegalovirus-specific hyperimmune
Normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomegalovirus-specific hyperimmune globulin (5 cc/kg dose)
Study: 30019993
Drug: Intraarterial selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial selective cooling infusion (IA‐SCI) with 350 ml 0.9% saline at 4℃ for 15 min
Study: 30019993
Drug: Intraarterial selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial selective cooling infusion (IA‐SCI) with mechanical thrombectomy (MT)
Study: 27033961
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (CSI), consisting of 3 injections over 12 months.
Study: 27033961
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT), consisting of 8-12 sessions over 12 months.
Study: 22491790
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus monitoring of mental state
Study: 20436446
Drug: Fluoxetine 20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20‐40 mg/day for at least 3 months and Tizanidine 4‐8 mg/day for at least 2 weeks
Study: 20436446
Drug: Therapeutic blockades
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic blockades of the occipital nerve and trigger points using local anesthetics (2.5 ml of 0.5% marcain solution and 0.5‐1 ml dexazone, for 1‐5 blockades) and needle reflexotherapy
Study: 17028904
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (50 micrograms every 6 hours, maximum three doses)
Study: 17028904
Drug: Intravaginal prostaglandin
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prostaglandin E2 (3 mg every 6 hours, maximum three doses)
Study: 16221261
Drug: Atrial therapies
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial therapies programmed off
Study: 12017400
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin regimen (preprandial inhaled intrapulmonary insulin plus a single bedtime Ultralente injection)
Study: 12017400
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin regimen (split/mixed insulin with 2 to 3 injections daily)
Study: 7794582
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg twice a day for 8 weeks
Study: 7037183
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of quazepam
Study: 28276596
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of vitamin D3
Study: 28276596
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (3750 IU/day)
Study: 26378683
Drug: Sequential Nephron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Nephron Blockade (SNB)
Study: 26378683
Drug: Sequential Renin-Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Renin-Angiotensin System Blockade (SRASB)
Study: 24738239
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with inclusion of sour milk bifidobacterin
Study: 19261235
Drug: Sertraline (Zoloft),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (Zoloft), Naltrexone (Revia), and compliance enhancement therapy
Study: 16445970
Drug: Memantine 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 0 mg daily (control)
Study: 9287228
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg every eight hours)
Study: 9287228
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg every eight hours) and Lamivudine (150 mg twice daily)
Study: 9287228
Drug: Indinavir, Zidovudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir, Zidovudine, and Lamivudine (three-drug combination)
Study: 9287228
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg every eight hours) and Zidovudine-Lamivudine (200 mg and 150 mg respectively)
Study: 8296259
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (200 micrograms inhaled)
Study: 3090216
Drug: D‐xylose absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐xylose absorption
Study: 26848517
Drug: Guided seven‐week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided seven‐week online Acceptance and Commitment Therapy (iACT) intervention
Study: 21137291
Drug: Curving sheath‐needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curving sheath‐needle multi‐direction rotating injection (CSNMRI) with ozone
Study: 21137291
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection method with ozone
Study: 17331708
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with medium chain triglycerides (MG)
Study: 17331708
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with isopropyl myristate (IPM)
Study: 17331708
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with light liquid paraffin (LP)
Study: 12136372
Drug: HRT containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT containing 2 mg estradiol valerate and 250 microg levonorgestrel
Study: 10652728
Drug: 9 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 MIU (33 micrograms) of n‐hIFN beta by subcutaneous route, three times per week, on alternate days, during one year
Study: 10652728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for the first 6 months, then switched to n‐hIFN beta treatment for the following 6 months)
Study: 10652728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (after switching to treatment)